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Abstract 
  We evaluated a needle-free injector (NFI), which has been studied as an 
administration device to the subcutaneous tissue, as a device to deliver drugs into skin 
tissues.  ShimaJet used for self-injection of insulin was selected as a spring-powered 
NFI in this study.  Weak (NFI-w) and strong (NFI-s) injectors were evaluated.  
Rhodamine 6G, as a model compound, was injected onto the skin surface of hairless rats 
and the skin distribution and amount released from the skin of the compound were 
followed.  A modified nozzle (able to inject at an angle of 45 degrees) was prepared in 
addition to the conventional dedicated nozzle.  The spring constants, nozzle shapes and 
penetration enhancer, 1-[2-(decylthio)ethyl] azacyclopentane-2-one (HPE-101), affected 
not only the skin distribution, but also the release profiles of rhodamine 6G.  In 
addition, the release profiles of rhodamine 6G after injection using NFI-w or NFI-s 
obeyed diffusion-controlled or membrane-controlled kinetics, respectively.  This 
difference was probably due to the skin site (depth) of rhodamine 6G delivered by the 
NFI.  Furthermore, HPE-101 increased the retention time of rhodamine 6G in the 
epidermis.  The present results suggested that an NFI can be a useful tool for 
enhanced drug delivery into skin.   
Key words: needle-free injection, transdermal drug delivery, ShimaJet, systemic drug 
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delivery, local drug delivery, high molecular weight compounds. 
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1.  Introduction 
The transdermal drug delivery system (TDDS) has several advantages for 
avoidance of the hepatic first-pass effect of drugs, long-acting sustained release of drugs, 
improved patient compliance and painless administration.  Furthermore, these 
ingenious matrix-typed and membrane-controlled transdermal patches provide safe 
drug delivery.  The Food and Drug Administration has approved many new 
transdermal patches containing rivastigmine and rotigotine (anti-Parkinson's drug), 
selegiline (antidepressant drug), buprenorphine (painkiller) and methylphenidate 
(attention-deficit hyperactivity disorder) since the beginning of this century.  These 
patches show high therapeutic effects in addition to scopolamine, nitroglycerine, 
isosorbide dinitrate, estradiol, testosterone and fentanyl patches by overcoming the 
primary barrier in the stratum corneum against drug entry through to the systemic 
circulation of topically applied drugs.  In addition, physicochemical methods, such as 
electroporation, microneedle and needle-free injection, are becoming popular to 
overcome the primary barrier in the stratum corneum for poorly permeable drugs.  
Many devices, Powder jectorTM, MacrofluxTM and Ionsis TM, have already been reported 
as effective tools to increase the skin permeation of drugs.  Among these techniques, 
needle-free injectors (NFI) have been investigated as an administration device not only 
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for high molecular weight compounds like insulin and human-growth hormone, but also 
for vaccine and gene delivery (Imoto and Konishi, 2005; Jackson et al., 2001; Agerso et 
al., 2002).  Drug administration using an NFI has advantages of painless and fearless 
injection (Jovanovic-Peterson et al., 1993; Theintz and Sizonenko, 1991) and the 
minimum skin damage caused by injection compared with a conventional needle 
injector.  Furthermore, the onset of therapeutic effects after administration using an 
NFI was much faster than with transdermal patches (Inoue et al., 1996), because 
needle-free injection directly delivered the drug into deep skin or muscle.  In this study, 
the possibility of drug delivery using needle-free injection, especially to skin tissues, 
was investigated to achieve long-term maintenance of drug concentration in the 
systemic circulation and long action of the therapeutic effects.  ShimaJet was selected 
as a spring-powered NFI that was used in clinical practice in Japan as an injection 
device for insulin.  The effect of the spring constant in ShimaJet was evaluated on the 
drug distribution in skin after topical injection.  Furthermore, the drug release profile 
from the injection site in skin was also investigated to clarify the usefulness of the NFI 
as a new drug delivery tool.  
 
2.  Theoretical 
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2.1.  Analysis of drug release 
 The drug release profile from the skin after needle-free injection was analyzed 
by the following eq. (1) (Ritger and Peppas, 1987).  
(1) 
where Q is the cumulative amount of drug released from skin, k is the release rate 
constant, t is time after injection and n is the release exponent.  When the release 
exponent, n, has a value of 0.5, the drug release shows Fickian release that follows W.I. 
Higuchi equation (Higuchi, 1962).  When the release exponent has a value greater 
than 0.5 (0.5 < n < 1), the release behaves as non-Fickian diffusion.  When release data 
are n = 1, the profile shows zero-order release. 
 
3.  Materials and methods 
3.1.  Materials and animals 
Rhodamine 6G was purchased from Tokyo Chemical Industry Co., Ltd (Tokyo, 
Japan).  1-[2-(Decylthio)ethyl] azacyclopentane-2-one (HPE-101) was a gift from 
Hisamitsu Pharmaceutical Co., Inc. (Tokyo, Japan).  All other reagents and solvents 
were of reagent or HPLC grade, and were used without further purification.  Male 
hairless rats (WBN/ILA-Ht, 200–250 g) were supplied either by the Life Science 
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Research Center, Josai University (Sakado, Saitama, Japan) or Ishikawa Experimental 
Animal Laboratory (Fukaya, Saitama, Japan).   
 
3.2.  Needle-free injector 
The spring-powered ShimaJet® (Shimadzu Co., Ltd., Kyoto, Japan) used in 
clinical practice in Japan was selected as a model NFI.  Two springs with different 
spring constants (10.6 N/mm: improved spring in ShimaJet® (NFI-w) and 15 N/mm: 
used in commercially available ShimaJet® (NFI-s)) were used to investigate the 
injection force and drug distribution in the skin.  A disposable dedicated nozzle (Fig. 
1a) was easily attached to ShimaJet® and solution was filled from the top of the nozzle.  
In addition to the disposable dedicated nozzle, the effect of nozzle shape on drug 
distribution in the skin was investigated using a modified nozzle (Fig. 1b).  The 
modified nozzle made from brass with an angle of 45 degrees was used to inject drug 
solution into skin (Fig. 1b).  These nozzles have the same fluid flow path width and 
orifice diameter.   
 
Fig. 1 
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3.3.  Measurement of injection force 
The injection force produced by ShimaJet® was measured by a TX-9A system 
(Fujimoto Laboratory, Tokyo, Japan).  Figure 2 shows a diagram of the TX-9 system, 
which was composed of a measurement stand with i) a digital oscilloscope (DL716; 
Yokogawa Electric Co. Inc., Tokyo, Japan), ii) a sensor amplifier (DA-16A) and a sensor 
(TX-9UA).  TX-9UA was divided into two main parts (Fig. 2b).  The upper part (Fig. 
2b) was a base to set ShimaJet® that was equipped with v) an injection port and viii) a 
level gauge confirmation window.  The lower part had v) a load cell, vi) a level gauge, 
vii) an injection port and viii) a pore.  The load cell was 1.0 mm high.  The injection 
force was measured using an oscilloscope to convert pressure (1 N) to voltage (1 V).  
The distance was fixed at 8.0 mm from the nozzle tip of ShimaJet® to high-sensitivity 
load cells in TX-9UA.  
 
Fig. 2 
 
3.4  Release experiment from excised skin 
The release test after topical injection of rhodamine 6G by ShimaJet® was 
performed using back skin excised from hairless rats.  After the rats had been 
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anesthetized by intraperitoneal injection of sodium pentobarbital (50 mg/kg), the back 
skin was excised, as explained in our previous paper (Okumura et al., 1989).  
Rhodamine 6G solution (1.0 mg/mL, 100 µL) was injected into the excised skin by NIF-w 
or NFI-s at a constant load of 4.9 N.  Next, the skin membrane was mounted in a 
Franz-type diffusion cell (effective diffusion area: 1.77 cm2).  The stratum corneum side 
was covered with Parafilm® and 6 mL of pH7.4 phosphate-buffered saline (PBS) was 
applied to the dermal side.  Periodically, samples of 0.50 mL were taken from the 
dermal side compartment, and then the same volume of PBS was added to keep the 
volume constant.  Rhodamine 6G concentration in the sample was determined by a 
fluorescence spectrophotometer (RF5300PC; Shimadzu) at excitation and emission 
wavelengths of 490 and 520 nm, respectively.  All animal experiments were approved 
by the ethics committee at Josai University and carried out following the guidance of 
Josai University. 
 
3.5.  Observation of drug distribution in skin  
Rhodamine 6G was injected into the excised skin by NFI-w or NFI-s.  The 
treated skin was embedded in Tissue-TeK O.T.C compound (Sakura Fine Tech, Osaka, 
Japan) and frozen, and horizontal or vertical sections of 20 µm thickness were prepared 
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using a cryostat (CM3050S; LEICA, Wetzlar, Germany).  The distribution of 
rhodamine 6G in each specimen was observed with a fluorescence microscope (CK40; 
Olympus, Tokyo, Japan). 
 
3.6.  Measurement of rhodamine 6G concentration in skin 
 The back skin excised from hairless rats was minced with forceps immediately 
after topical injection of rhodamine 6G solution.  The minced skin tissues were 
homogenized with a Polytoron homogenizer (Kinematica, Lucerne, Switzerland) in 
methanol, and centrifuged at 15,000 rpm for 3 min at 4°C.  Rhodamine 6G 
concentration in the supernatant was measured using the fluorescence 
spectrophotometer.  Furthermore, rhodamine 6G concentration in skin slices (20 µm 
thickness) was measured after extraction with methanol.   
 
3.7  In vivo experiment 
 The time course of plasma concentration of rhodamine 6G was followed after 
intravenous bolus injection using a 27-gauge syringe or administration of the compound 
to hairless rat back skin with NFI-s at a dose of 1.0 mg/mL (100 µL).  Blood samples 
were periodically withdrawn through the jugular vein.  Blood samples were 
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centrifuged at 15,000 g for 5 min at 4°C to obtain plasma. Rhodamine 6G concentration 
in plasma diluted by saline was measured using a fluorescence spectrophotometer.  
Animal experiments were performed under anesthesia using i.p. injection of urethane.  
 
3.8.  Simulation 
 Plasma concentration-time profiles after injection of rhodamine 6G into rat 
back skin by NFI-s were simulated by following eq. 2.   
 
(2) 
where C is the plasma concentratiopn of rhodamine 6G and V and kel are the apparent 
volume of distribution and the elimination rate constant, respectively, of rhodamine 6G.  
The rate constant k was caluculated from eq. 1 and V and kel were obtained from the 
blood concentration-time profile after bolus intraveous administration.   
 
3.  RESULTS  
3.1.  Injection force –time profiles after injection by ShimaJet®  
Figure 3a and b show the time course of injection force after injection using 
NFI-w and NFI-s, respectively, through a normal nozzle.  Injection force increased with 
12 
 
an increase in the injection volume from 50 to 250 µL both in NFI-w and NFI-s 
treatment.  The maximum injection force, however, was almost constant above 100 µL 
of the injection volume.  The decreased profiles of injection force after achieving the 
maximum injection force were different between two injectors below and above 100 µL.  
Injection force immediately decreased after reaching the maximum pressure in the case 
of injection volume under 100 µL, whereas injection force gradually decreased and the 
duration of high injection force was dependent on the injection volume in the case of 
injection volume more than 100 µL.  Figure 3c shows the time course of injection force 
after injection by NFI-s through a modified nozzle.  The increase of injection force by 
the increase in injection volume with the modified nozzle showed the same tendency as 
using the normal nozzle.  The maximum injection force after injection through the 
modified nozzle, however, was much lower than that through the normal nozzle. 
 
Fig. 3 
 
3.2.  Amount of rhodamine 6G delivered into skin by ShimaJet® 
Figure 4 summarizes the amount of rhodamine 6G delivered into the whole 
skin, epidermis and dermis.  The amounts of rhodamine 6G delivered in the whole skin 
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by NFI-w and NFI-s through the normal nozzle were 50.1 and 72.8 µg, respectively.  
Rhodamine 6G was also detected in the nozzle and on the skin surface.  Interestingly, 
the amount of rhodamine 6G delivered was much different between the two springs.  
NFI-w with a normal nozzle delivered rhodamine 6G to the shallow part of the skin, and 
the amount in the shallow skin was about 1.5 times higher than in the dermis, whereas 
NFI-s with a normal nozzle mainly delivered rhodamine 6G through the dermis.  When 
NFI-s with a modified nozzle was used, only 9.5 µg rhodamine 6G was delivered into the 
whole skin and most of the compound was detected in the dermis.  
 
Fig. 4 
 
3.3.  Observation of skin distribution of rhodamine 6G  
Figure 5a and b show fluorescence micrographs with rhodamine 6G 
distribution in the skin after injections using NFI-w and NFI-s, respectively.  Shallow 
distribution of rhodamine 6G was observed in the shallow part of the skin after injection 
using NFI-w.  On the other hand, rhodamine 6G was observed in the whole skin area 
after injection using NFI-s.  Rhodamine 6G distribution after injection uisng NFI-s 
with a modified nozzle was slightly observed in the skin and the fluorescence intensity 
14 
 
of rhodamine 6G was much weaker than that after injections using NFI-w and NFI-s 
with the normal nozzle (data not shown).  Subsequently, only the normal nozzle was 
used in this experiment because the modified nozzle could not effectively deliver 
rhodamine 6G into the skin.  Figure 5c and d show the amount of rhodamine 6G at 
different depths from the skin surface after injection uisng NFI-w and NFI-s with a 
normal nozzle.  NFI-w mainly delivered rhodamine 6G into the shallow part of skin: 
Most of the rhodamine 6G was detected in the skin up to 500 µm deep from the skin 
surface.  On the other hand, NFI-s homogeneously delivered rhodamine 6G into the 
skin; the amount of rhodamine 6G in the skin was consistently equal at different depths 
from the skin surface to the bottom of the dermis.  These results of rhodamine 6G 
distribution at different depths corresponded to the results of fluorescence observation 
(Fig. 4).   
 
Fig. 5 
 
3.4.  Evaluation of rhodamine 6G release from injected skin  
Figure 6 and Table 1 show release profiles of rhodamine 6G from the skin depot 
produced by needle-free injection.  The release rate constant, k, and the release 
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exponent, n, were calculated from the double logarithmic plot of the cumulative amount 
of rhodamine 6G released-time profiles.  Table 1 summarizes the calculated k and n 
values.  The k and n values for NIF-w were 1.18 h-1 and 0.7, respectively, whereas 
those of NFI-s were 10.5 h-1 and 0.5.  The k value of NFI-w was much slower than that 
of NFI-s.  Next, the effect of a skin-penetration enhancer, HPE-101, was investigated 
on the amount of rhodamine 6G released from its injected depot in the skin and on 
rhodamine 6G distribution.  As a formulation, HPE-101 was added at a concentration 
of 1.0% to 1.0 mg/ml rhodamine 6G solution and homogenized to obtain an O/W typed 
emulsion.  Figure 6 and Table 1 show the time course of the amount of rhodamine 6G 
released after injection of the O/W emulsion by NFI-s and rhodamine 6G release 
parameters from O/W emulsion-injected skin.  The rhodamine 6G release decreased by 
injecting the O/W emulsion compared with the drug solution and the k and n values 
were 0.78 h-1 and 0.66, respectively.  The amount of rhodamine 6G delivered into the 
skin was 36.9 µg, which was comparatively low regardless of NFI-s injection (data not 
shown).    
 
Fig. 6, Table 1 
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3.5.  Rhodamine 6G concentration in skin after release experiment  
Figure 7 shows rhodamine 6G concentration in the skin 12 h after the release 
experiment using its solution or O/W emulsion.  Figure 7a, b and c indicate the 
rhodamine concentration in the whole skin, epidermis and dermis, respectively.  
Interestingly, rhodamine 6G concentration fell markedly after injection using NFI-s 
compared to the results shown in Fig. 4b and c, whereas most rhodamine 6G remained 
12 h after injection using NFI-w.  Furthermore, rhodamine 6G was retained over 12 h 
for O/W emulsion-injected skin.   
 
Fig. 7 
 
3.6.  Plasma concentration of rhodamine 6G after injection using NFI-s 
The elimination kinetics of rhodamine 6G after bolus i.v. injection in rats 
obeyed the linear 1-compartment model (data not shown).  The obtained elimination 
rate constant, kel, and distribution volume, V, were 1.15 h-1 and 2.0 L, respectively.  
Figure 8a shows the observed and simulated plasma concentrations after injection of 
100 µL of 1.0 mg/mL rhodamine 6G solution by NIF-s to the back skin in rats.  The 
simulated curve was obtained by eq. 2.  The Cmax was observed 15 min after injection 
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and the plasma concentration gradually decreased over 5 h.  The simulated curve did 
not correspond to the observed value, especially just after the injection.  The simulated 
values were calculated under assumption that rhodamin 6G would be absorbed into 
cutaneous microvascular vessels just after it passed through the whole skin.  These 
microvascular vessels, however, exist in the dermis, not at the end of the dermis.  Thus 
in vivo absorption of rhodamin 6G must start a little earlier than in vitro reaching into 
the end of the dermis and part of rhodamin 6G might be directly absorbed just after its 
injection into the skin.  Figure 8b shows the observed value and the sum of the 
simulated values calculated by eq. 2.   The simulated values were assumed to be part 
of rhodamine 6G, which was directly transported from the skin into blood just after 
NFI-s injection.  The amount of rhodamine 6G transferred into the blood was fixed at 
11.8 µg.  This summarized value was very close to the observed value.  Thus, 
rhodamine was thought to be transported from the skin to the systemic circulation after 
NFI-s injection. 
 
Fig. 8 
 
4.  Discussion 
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Breaking through the stratum corneum barrier is the key for developing TDDS.  
Traditional TDDS limited the molecular size of drugs to less than 500 Da, as explained 
by the 500 Dalton rule (Bos and Meinardi, 2000).  Thus, the formulation of TDDS is not 
suitable for high molecule hydrophilic drugs, such as proteins and vaccines.  
Needle-free injection using ShimaJet enabled not only direct drug delivery to the 
target site of the skin, but is also a systemic drug delivery system bypassing the 
stratum corneum barrier.  Other physical approaches, such as microneedles (Prausnitz, 
2004) and electroporation (Tokudome and Sugibayashi, 2004), have also been 
investigated as promising means to overcome the barrier function of the stratum 
corneum.  Among these methods, needle-free injection would provide a high dose of 
drug into the skin.  Many reports have been found on the effectiveness of a needle-free 
injector as a drug delivery device (Baxter and Mitragotri, 2005; Schramm and 
Mitragotri, 2002).  Few studies, however, have reported the dermatokinetics and 
distribution of injected drugs after needle-free injection.  On the other hand, several 
studies have reported the dermatokinetics of the drug and translocation to the systemic 
circulation from the injected site after subcutaneous injection (Yoshida et al., 2008 a,b).  
The drug disposition in the skin after subcutaneous injection was very different from 
after application of traditional TDDS.  The amount of rhodamine 6G delivered to the 
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skin after injection of 100 µL of 1.0 mg/mL rhodamine 6G by ShimaJet was greatly 
affected by the spring constant and nozzle type.  The low value of the maximum 
injection force produced by NFI-w through a normal nozzle and NFI-s through a 
modified nozzle may not be enough to break through the stratum corneum barrier.  
The NFI-w injection, however, was capable of selectively delivering rhodamine 6G into 
the epidermis.  Thus, the present results suggested that the ingenuity of device or 
formulation might be very important for selective drug delivery into the skin, but that 
improvement of the device will be required to increase the delivery amount of 
rhodamine 6G. 
The release profiles of rhodamine 6G after injection using NFI-w and NFI-s 
were supposed to be diffusion-controlled and membrane-controlled, respectively (Ritger 
and Peppas, 1987).  These different release profiles depended on the skin distributions 
after injection using NFI-w and NFI-s.  The distributed rhodamine 6G might diffuse 
along different diffusion pathways into skin.  Furthermore, the physicochemical 
characteristics of rhodamine 6G might also be related to the release profiles.  A large 
volume of solution flowing into the skin at one time would alter the physicochemical and 
structural characteristics of the skin tissues.  The pH of the skin surface and dermis is 
4.5 to 5.5 and 7.2, respectively (Ohman and Vahlquist, 1998) and the pKa of rhodamine 
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6G is 7.5.  Thus, rhodamine 6G mainly exists as a cation and might interact with 
negatively charged cutaneous cells in the epidermis.  Application of a base such as 
lidocaine using NFI-w would show the early onset and long-acting effect (data not 
shown).  Detail investigations are necessary to clarify the mechanism of drug release 
from the skin depot made by an NFI.  The emulsion prepared using HPE-101 shows 
the unique characteristics of rhodamine 6G release from the depot.  The amount of 
rhodamine 6G delivered to the skin after injection of the emulsion by NFI-s was lower 
than that after injection of rhodamine 6G solution.  Although the amount of rhodamine 
6G delivered was low after injection of the emulsion, the retention time of rhodamine 
6G in the epidermis increased with a decrease in the release rate from skin.  Emulsion 
delivery using an NFI might be effective for topically effective drugs, especially those 
having early onset and long-acting therapeutics.  This method could be applicable also 
to biodegradable nano-/microsphere suspensions and liposome formulations. 
Needle-free injection utilizes compressed gas to deliver drugs into skin 
(Mumper and Cui, 2003).  We selected a device, ShimaJet , which utilizes a spring 
power system.   The skin depth of the drug was controllable by modifying the nozzle 
shape.  This modified nozzle could be used not only in the spring-powered device 
ShimaJetbut also in a compressed-gas-powered Biojector.  
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The injection volume and formulation administered into the cutaneous tissues 
had a great effect on the dermatokinetics of drugs (Yoshida et al., 2007).  The NFI-s 
delivered a large amount of solution into the skin and this delivery technique might 
alter the dermatokinetics of the drug compared to traditional TDDS.  The present 
results suggested that an NFI would be effective as a novel transdermal drug delivery 
system using the epidermis or epidermis/dermis as a drug depot or a drug release 
controlled reservoir.  The theoretical blood concentration calculated using the in vitro 
release data was different from the observed values.  This difference might be due to 
the migration of rhodamine 6G into microvascular vessels in the skin, suggesting that 
direct migration of the drug into the microvascular vessels was taking place after 
injection by NFI-s.  Thus, NFI-w and NFI-s are useful devices for effective systemic 
and local delivery of drugs, respectively.  
 
5．Conclusions 
The depth of rhodamine 6G delivered into the skin and its release after injecton 
by ShimaJet could be controlled by enhancing the spring constant, outlet shape of the 
nozzle and the formulation.  In the present results, however, rhodamine 6G delivery 
through the modified nozzle and that using the emulsion indicated a lower drug 
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delivery rate compared to solution injection by NFI-s through the normal nozzle.  
Therefore, improvement of the delivery technique using ShimaJet is required to obtain 
depth-controllable drug delivery.  Currently, the relationships between the 
drug-delivery depth or the retention time of the drug in skin and the onset or lasting 
pharmacological effects are being investigated.  In the future, efficient and controllable 
delivery will be obtained by needle-free injection. 
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Table 1  Fickian release parameters of rhodamine 6G  
 k (h-1) n Release type 
NFI-w 1.18 0.70 Non-Fickan release 
NFI-s 10.5 0.50 Fickian release 
NFI-s (HPE-101) 0.78 0.66 Non-Fickan release 
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Figure Captions 
 
Fig. 1  Diagram of normal and modified nozzles of ShimaJet . 
a) Commercially available disposal nozzle: i) injection port, ii) nozzle-fixing bar,  
iii) screw thread, iv) solution-filling space.   
b) Modified nozzle: v) injection port, vi) solution-filling space made of brass.  
 
Fig. 2  Setup for TX-9A system to detect injection force of ShimaJet . 
a) TX-9 system: i) digital oscilloscope, ii) sensor amplifier, iii) TX-9UA, iv) 
ShimaJet®. b) diagram of TX-9: v) load cell, vi) level gauge, vii) injection port, 
viii) pore.  
 
Fig. 3  Effect of nozzle type and injection volume on the time course of injection force 
after injection by ShimaJet .  
(a) NFI-w with normal nozzle, (b) NFI-s with normal nozzle, (c) NFI-s with 
modified nozzle 
Lines:  ―: 50 µL, ∙∙∙∙: 100  µL, ―: 125 µL, ∙∙∙∙: 250 µL for injection volume. 
 
Fig. 4    Effect of nozzle type on the rhodamine 6G concentration in skin after injection 
by ShimaJet®. 
Rhodamine 6G concentration in whole skin (a), epidermis (b) and dermis (c).  
Gray column: NFI-w with normal nozzle, open column: NFI-s with normal nozzle, 
closed column: NFI-s with modified nozzle.  Abbreviations: normal nozzle (NZ), 
modified nozzle (MN). 
 
Fig. 5  Distribution of rhodamine 6G in skin after injection by NFI-w or NFI-s.  
a) and b) fluorescence image of rhodamine 6G in the skin, c) and d) rhodamine 
concentration in the skin. 
 
Fig. 6  Effect of formulations on rhodamine 6G release from rat skin after injection by 
NFI-s. 
Symbols: : Injection of 1 mg/mL rhodamine 6G solution by NFI-s, : Injection 
of 1 mg/mL rhodamine 6G solution by NFI-w, : Injection of 1mg/mL rhodamine 
6G in 1% pirotiodecane by NFI-s  
 
Fig. 7  Skin concentration of rhodamine 6G 12h after skin permeation experiment.  
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Rhodamin 6G concentration in whole skin (a), epidermis (b) and dermis (c).  
      Gray bar: Rhodamine 6G injection by NFI-w, white bar: rhodamine injection by 
NFI-s, black bar: rhodamine 6G with pirotiodecane injection by NFI-s. 
 
Fig. 8   Plasma concentration of rhodamine 6G after NFI-s injection. 
(a): observed () and simulated values obtained by eq. 2() .  
      (b): observed value (), simulated value calculated by eq. (2) (), simulated value 
after i.v. injection of rhodamine 6G () and the sum of that calculated by eq. (2) 
and the simulated value after i.v. injection of rhodamine 6G ().  
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